SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations.. The company’s 5.9 million shares will be offered at $16 ...

Aardvark has yet to set the value of its planned IPO but said in its Securities and Exchange Commission filing Jan. 23 that it expects to use the proceeds to “advance the clinical development of ...